Search Results
Jun 01, 2026, 03:01 ET iScooter Celebrates 11 Years of Innovation with Anniversary Sale Across Europe
Choice: The EB1S electric bike offers an eco-friendly alternative for urban travel, featuring a compact design suited for daily city commutes. With a 500W motor and app-enabled controls, the EB1S provides a practical, green transportation option for riders looking to reduce their carbon footprint.Special
More news about: iScooter
Jun 01, 2026, 03:00 ET Petal Ads prezentuje kompleksowe inteligentne rozwiązanie marketingowe dla sektora kultury i turystyki na targach ITB China 2026
r. /PRNewswire/ -- W dniach 26-28 maja w Szanghaju odbyły się targi ITB China 2026, które zgromadziły ponad 900 instytucji i przedsiębiorstw z sektora kultury i turystyki z 85 krajów i regionów. Petal Ads, platforma marketingowa Huawei obejmująca wszystkie scenariusze użytkowania w ekosystemie HarmonyOS,
More news about: Huawei Consumer Business Group
Jun 01, 2026, 03:00 ET UGREEN Unveils the "Game Day Kit" -- A Soccer Ball-Shaped Tracker and Fast-Charging Essentials for Every Game Day and Beyond
strips on the tracker improve visibility in low-light environments.Nexode Power Bank 10000mAh 55W: Reliable Power for Days OutThe Nexode Power Bank 10000mAh 55W delivers up to 55W fast charging in a compact design that's easy to hold. It supports multiple fast-charging protocols, powers
More news about: UGREEN GROUP LIMITED
Jun 01, 2026, 00:00 ET Minghui Pharmaceutical and Qilu Pharmaceutical Co-Announces Updated Clinical Data of MHB088C (QLC5508) from Phase I/II study in Heavily Pretreated mCRPC Patients at 2026 ASCO Annual Meeting
6%-84.3%).Among 40 patients treated at the 2.0 mg/kg Q2W dose, median rPFS was also not reached (95% CI, 13.1-NE), with a 12-month rPFS rate of 78.6% (95% CI, 50.7%-91.
More news about: Minghui Pharmaceutical
May 31, 2026, 22:15 ET 威強電 (IEI) 於 2026 COMPUTEX 展出強韌邊緣 AI 平台：推動 AI 在工業應用的落地部署
TANK-XM811 與 DRPC-W-ASL 平台透過整合三菱電機 (Mitsubishi Electric) 的 SWM-G 運動控制與基於 ROS2 架構的 RV-2FR 機械手臂控制，實現極具彈性的控制架構。因應 CRA 資安規範，提供快速資安漏洞應變能力：產品開發基於
More news about: IEI Integration Corp.
May 31, 2026, 22:12 ET IEI Showcases Resilient Edge AI Platforms at COMPUTEX 2026: Advancing AI Deployment Across Industrial Applications
TANK-XM811 and DRPC-W-ASL platforms enable flexible control architectures by integrating Mitsubishi Electric SWM-G motion control with ROS2-based RV-2FR robot control.CRA
More news about: IEI Integration Corp.
May 31, 2026, 22:12 ET IEI Showcases Resilient Edge AI Platforms at COMPUTEX 2026: Advancing AI Deployment Across Industrial Applications
TANK-XM811 and DRPC-W-ASL platforms enable flexible control architectures by integrating Mitsubishi Electric SWM-G motion control with ROS2-based RV-2FR robot control.CRA
More news about: IEI Integration Corp.
May 31, 2026, 20:15 ET ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
was dosed at 10–45 mg/kg, once every 3 weeks (Q3W);(2) Group 2 (2/3L NSCLC combination therapy), n=9: CS2009 was dosed at 20 or 30 mg/kg, Q3W plus docetaxel;(3) Group 3 (1L NSCLC monotherapy ), n=23: CS2009 was dosed at 20 or 30 mg/kg, Q3W;(4) Group 4 (1L squamous NSCLC combination
More news about: CStone Pharmaceuticals
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
Among the 58 patients with EGFR wild-type adenoNSCLC, 30 patients received IBI363 at 0.6 mg/kg Q2W or 1 mg/kg Q2W or 1.5 mg/kg Q3W, and 25 patients received IBI363 at 3 mg/kg Q3W. In the 3 mg/kg dose group, the median PFS reached 4.2 (95%CI 3.0, 7.0) months, and the median OS achieved
More news about: Innovent Biologics
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
3→1.5 mg/kg IBI363 dose group:3 mg/kg + PDC in cycle 1, followed by 1.5 mg/kg once every 3 weeks (Q3W) + PDC1.5 mg/kg IBI363 dose group: 1.5 mg/kg Q3W + PDC3 mg/kg IBI363 dose group: 3 mg/kg Q3W + PDCAmong the 80 patients, the median age was 64 years, 88.8% were male, 81.3%
More news about: Innovent Biologics
May 31, 2026, 20:00 ET D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC
NSCLCFifty-two patients with previously untreated G12Cmut NSCLC received elisrasib 600 mg once daily in combination with pembrolizumab 200 mg every 3 weeks (Q3W), with a median study follow-up of 5.7 months. Notably, the dose of elisrasib used in combination is elisrasib's RP2D at 600mg QD which provides complete
More news about: D3 Bio
May 31, 2026, 17:36 ET Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib) at ASCO 2026
Blumenthal, D. T., Touat, M., Peters, K. B., Clarke, J., Mendez, J., Yust-Katz, S., Welsh, L., Mason, W. P., Ducray, F., Umemura, Y., Nabors, B., Holdhoff, M., Hottinger, A. F., Arakawa, Y., Sepulveda, J. M., Wick, W., Soffietti, R., … Cloughesy, T. F. (2023). Vorasidenib in idh1- or IDH2-mutant low-grade glioma.
More news about: Servier Pharmaceuticals
May 31, 2026, 08:29 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
therapy.RYBREVANT FASPRO™ was administered on a weekly schedule during the initial treatment period followed by dosing every three weeks (Q3W), with weight-based dosing adjustments. The primary endpoint across cohorts is overall response rate (ORR), as assessed by investigators, using RECIST
More news about: Johnson & Johnson
May 31, 2026, 05:31 ET Zendure en Sunergy bundelen hun krachten om slim energiebeheer voor woningen in Nederland te versnellen.
2400 AC+, ontworpen om naadloos te integreren met bestaande PV-systemen. Met een AC-gekoppeld plug-and-play-ontwerp, tweerichtingsopbrengst tot 2400 W en een uitbreidbare capaciteit van 2,4 kWh tot 16,8 kWh biedt het een flexibele en schaalbare opslagoplossing.Met behulp van AI-gedreven energiebeheer
More news about: Zendure DE GmbH
May 31, 2026, 05:21 ET Zendure und Sunergy gehen Partnerschaft ein, um das Energiemanagement für Smart Homes in den Niederlanden zu beschleunigen
Integration in bestehende PV-Anlagen entwickelt wurde. Mit einem AC-gekoppelten Plug-and-Play-Design, einer bidirektionalen Leistung von bis zu 2400 W und einer erweiterbaren Kapazität von 2,4 kWh bis 16,8 kWh bietet er eine flexible und skalierbare Speicherlösung.Mit Hilfe von KI-gesteuertem
More news about: Zendure DE GmbH
May 31, 2026, 05:13 ET Zendure et Sunergy s'associent pour accélérer la gestion intelligente de l'énergie résidentielle aux Pays-Bas
manière transparente aux systèmes photovoltaïques existants. Avec une conception plug-and-play à couplage AC, une sortie bidirectionnelle jusqu'à 2 400 W et une capacité extensible de 2,4 kWh à 16,8 kWh, il offre une solution de stockage flexible et évolutive.Alimenté par une gestion de l'énergie
More news about: Zendure DE GmbH
May 30, 2026, 08:00 ET The Rosen Law Firm, P.A. Continues to Remind Investors of the Proposed Class Action Settlement on Behalf of Purchasers of Sun Communities, Inc. Publicly-Traded Common Stock - SUI
will be held on July 29, 2026 at 10:30 a.m. before the Honorable Linda V. Parker, United States District Court for the Eastern District of Michigan, 231 W. Lafayette Blvd., Room 206, Detroit, MI 48226, for the purpose of determining whether: (1) the proposed Settlement of the claims in the above-captioned
More news about: The Rosen Law Firm, P.A.
May 29, 2026, 14:03 ET OLIVE YOUNG DEBUTS IN THE U.S. WITH FIRST STORE IN PASADENA
What is OLIVE YOUNG bringing to the U.S. beauty market?Located at 58 W Colorado Blvd, the 8,647-square-foot OLIVE YOUNG Pasadena marks a significant milestone in OLIVE YOUNG's global expansion, bringing Korea's leading beauty
More news about: CJ OLIVE YOUNG
May 29, 2026, 14:00 ET RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
undertake to update any forward-looking statement as a result of new information or future events or developments.###* Joel W. Neal, M.D., Ph.D., has served as a consultant to Johnson & Johnson; he has not been paid for any media work.† Once monthly after
More news about: Johnson & Johnson
May 29, 2026, 12:00 ET In HelloNation, Tax Expert Sal Julian Explains How Strategic Planning Changes Long-Term Tax Outcomes
distinction between these two approaches carries real financial weight. The article uses a high-income professional as an illustration: someone with W-2 earnings, a rental property, and appreciated securities in a brokerage account. Whether the rental generates a usable deduction or a suspended passive
More news about: HelloNation
May 29, 2026, 11:54 ET Haier Biomedical zdobywa podwójne pierwsze miejsce w globalnym raporcie Euromonitor dotyczącym wyposażenia laboratoriów nauk biologicznych i finalizuje trzyetapową globalną ekspansję
Biomedical jest sprawdzonym partnerem w zakresie organizacji pracy laboratoryjnej. Standardy serwisowe opracowane w USA i Wielkiej Brytanii są obecnie wdrażane również w Unii Europejskiej, Azji Południowo-Wschodniej i Azji Południowej.W I kwartale 2026 roku przychody w Niemczech, Australii i Kanadzie
More news about: Haier Biomedical
May 29, 2026, 11:07 ET Ramaco Resources CEO Randall W. Atkins Appears on CNBC's Morning Call to Discuss Critical Minerals and Energy Market Trends
Randall W. Atkins, appeared on CNBC's Morning Call to discuss the Company's coal and critical minerals platform in Central Appalachia and Wyoming, and the impact on global coal markets amid energy market disruptions tied to the ongoing conflict in Iran. During the interview, Randall W. Atkins highlighted
More news about: Ramaco Resources, Inc.
May 29, 2026, 11:00 ET Health Tech Founders Outperform Their Own Brands on LinkedIn
5W is the AI Communications Firm — building brand authority across the platforms where decisions now happen: ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews, alongside earned media, digital, and influencer channels. 5W combines public relations, digital
More news about: 5W Public Relations
May 29, 2026, 10:54 ET PeproMene Bio、、EHA 2026において、B細胞リンパ腫（過去にCD19 CAR T細胞療法が奏効しなかった症例を含む）に対するPMB-CT01（BAFF-R CAR T細胞療法）の良好な安全性および持続的な奏効を強調する口頭発表を行うことを発表
T療法後に進行した形質転換FL（tFL）患者）が、最初の病勢評価でCRを達成したことです。tFLは、確立された治療選択肢が限られている侵攻性のリンパ腫です。「CD19のCAR T療法後にがんが進行した場合、患者は重大なアンメット・メディカル・ニーズに直面し、残された治療選択肢は非常に限られています」と、PeproMene Bio.の科学的創始者であるLarry W. Kwak医学博士は述べています。「これらの持続的なCRは、BAFF-Rが新規の標的であることを臨床的に証明するものであり、一方、現在までに観察された良好な安全性プロファイルは、将来、外来患者を対象とした地域がん領域での使用や、難治性自己免疫疾患でのさらなる研究の裏付けとなる可能性があります。」発表内容抄録タイトル
More news about: PeproMene Bio, Inc.
May 29, 2026, 10:00 ET AI Engines Already Enforce the GENIUS Act -- New 5W Stablecoin Trust Index Ranks 25 Tokens, Largest Comes in Tenth
email gate. About 5W 5W is the AI Communications Firm, building brand authority across the platforms where decisions now happen — ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews — alongside earned media, digital, and influencer channels. 5W combines public relations,
More news about: 5W Public Relations